Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016–2018

Hernandez, 2018, Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States, BMC Cancer, 18, 44, 10.1186/s12885-017-3922-0 Macedo, 2017, Bone metastases: an overview, Oncol Rev, 11, 321 Rich, 2018, Update of the systematic review of palliative radiation therapy fractionation for bone metastases, Radiother Oncol, 126, 547, 10.1016/j.radonc.2018.01.003 Lutz, 2017, Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline, Pract Radiat Oncol, 7, 4, 10.1016/j.prro.2016.08.001 Fischer-Valuck, 2018, Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: a hospital-based analysis of patterns of care, RT fractionation scheme, and overall survival, Cancer Med, 7, 4240, 10.1002/cam4.1655 Rutter, 2015, Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States, Int J Radiat Oncol Biol Phys, 91, 548, 10.1016/j.ijrobp.2014.10.045 Gupta A, Wang P, Sedhom R, et al. Physician practice variability in the use of extended-fraction radiation therapy for bone metastases: are we choosing wisely? JCO Oncol Pract 2020:JOP1900633. Nguyen, 2019, Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial, JAMA Oncol, 5, 872, 10.1001/jamaoncol.2019.0192 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 10.1001/jamaoncol.2020.0147 Gomez, 2019, Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201 Pan, 2011, A survey of stereotactic body radiotherapy use in the United States, Cancer, 117, 4566, 10.1002/cncr.26067 Yamada, 2008, High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions, Int J Radiat Oncol Biol Phys, 71, 484, 10.1016/j.ijrobp.2007.11.046 Laufer, 2013, The NOMS framework: approach to the treatment of spinal metastatic tumors, Oncologist, 18, 744, 10.1634/theoncologist.2012-0293 Chow, 2014, Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial, Lancet Oncol, 15, 164, 10.1016/S1470-2045(13)70556-4 Lutz, 2011, Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline, Int J Radiat Oncol Biol Phys, 79, 965, 10.1016/j.ijrobp.2010.11.026 Logan, 2019, Trends in radiation for bone metastasis during a period of multiple national quality improvement initiatives, J Oncol Pract, 15, e356, 10.1200/JOP.18.00588 Yamada, 2017, The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery, Neurosurg Focus, 42, E6, 10.3171/2016.9.FOCUS16369 Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) 2009;34(22 Suppl):S78–92. Garg, 2012, Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases, Cancer, 118, 5069, 10.1002/cncr.27530 Sprave, 2018, Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy, Radiother Oncol, 128, 274, 10.1016/j.radonc.2018.04.030 Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 2020:JCO2000818. Lee, 2020, Assessment of parking fees at national cancer institute-designated cancer treatment centers, JAMA Oncol, 10.1001/jamaoncol.2020.1475 Muller, 2020, STAT RAD: prospective dose escalation clinical trial of single fraction scan-plan-QA-treat stereotactic body radiation therapy for painful osseous metastases, Pract Radiat Oncol, 10.1016/j.prro.2020.03.008 Chow, 2019, Single vs multiple fraction palliative radiation therapy for bone metastases: cumulative meta-analysis, Radiother Oncol, 141, 56, 10.1016/j.radonc.2019.06.037 Krishnan, 2014, Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model, Cancer, 120, 134, 10.1002/cncr.28408 Zucker, 2018, The NEAT predictive model for survival in patients with advanced cancer, Cancer Res Treat, 50, 1433, 10.4143/crt.2017.223 Rettenmaier, 2012, Regional variations in medical spending and utilization: a longitudinal analysis of US Medicare population, Health Econ., 21, 67, 10.1002/hec.1700